Neuromuscular Drugs Ref

DESCRIPTION: IMPORTANT: This app is intended for use by qualified healthcare professionals only. Always seek the advice of a qualified clinician before making any medical or prescribing decisions. Neuromuscular Drugs Reference is a comprehensive evidence-based drug reference for neuromuscular pharmacology. Built for neurologists, anaesthetists, intensivists, and allied health professionals managing patients with neuromuscular disease. MYASTHENIA GRAVIS DRUGS - Acetylcholinesterase inhibitors: pyridostigmine full dosing protocol, neostigmine IV use, propantheline for side effects, cholinergic crisis recognition (SLUDGE) - Corticosteroids: prednisolone slow titration protocol, initial worsening warning (30-50%), bone and gastric protection, IV methylprednisolone for ICI toxicity - Steroid-sparing agents: azathioprine with TPMT testing requirement, mycophenolate mofetil, ciclosporin — full monitoring table with pre-treatment tests, ongoing tests, and onset timelines - Biologics: rituximab (anti-CD20, best in anti-MuSK MG), eculizumab (NICE TA6022 approved, meningococcal vaccination protocol), efgartigimod/Vyvgart (NICE 2022, IV and SC formulations), rozanolixizumab/Rystiggo (MHRA 2023), zilucoplan/Zilbrysq (MHRA 2023, daily SC) NEUROMUSCULAR BLOCKERS - Suxamethonium: RSI dosing, hyperkalaemia mechanism in denervated muscle, full contraindication list, malignant hyperthermia trigger - Non-depolarising agents - Reversal agents: sugammadex dosing (2/4/16mg/kg), why it is preferred over neostigmine in MG, neostigmine plus glycopyrrolate protocol, train-of-four monitoring principles - Special populations: GBS, MG, renal failure, hepatic failure, burns, malignant hyperthermia, LEMS — drug choice table GBS AND CIDP DRUGS - IVIg: full dosing protocol for GBS and MG crisis, CIDP acute and maintenance dosing, start rates, brand information (Privigen, Kiovig, Flebogamma), IgA check requirement, pre-medication, AKI avoidance, side effects management table - Plasma exchange: 5-session protocol, replacement fluid choice, contraindications, complications table (hypotension, hypocalcaemia, coagulopathy) - CIDP maintenance: subcutaneous immunoglobulin (SCIg) with PATH trial evidence, Hizentra dosing, prednisolone protocol, PREDICT trial summary - Supportive drugs LAMBERT-EATON DRUGS - Amifampridine (Firdapse) - Pyridostigmine adjunct dosing in LEMS - Malignancy screen protocol - IVIg and plasma exchange in acute LEMS BOTULINUM TOXIN - All four UK licensed preparations - Six therapeutic indications with doses - Complications table: STATIN MYOPATHY - Full SAMS spectrum table - Risk factors - Rhabdomyolysis 6-step emergency protocol - SANAM (statin-associated necrotising autoimmune myopathy) - Statin re-introduction strategy ICU NEUROMUSCULAR DRUGS - NMBA indications, TOF monitoring principles, limiting duration to 24-48h - Sedation agents: - Opioids - ICUAW prevention drug strategies DRUG INTERACTIONS - Comprehensive table of drugs worsening MG - Drugs prolonging NMJ blocker duration - Safe antiemetics in MG - Antiemetics to AVOID in MG INTERACTIVE FEATURES - Drug search: 30+ searchable entries across all sections — tap result to navigate directly to the relevant section - Quiz mode: 10 clinical pharmacology questions with detailed explanations covering all 9 sections - My Notes: personal clinical notes saved during the session - Font size adjustment: A- / A+ text scaling for bedside use - 25+ tappable references including NICE TA6022, REGAIN trial, ADAPT trial, SID-GBS 2023, PATH trial, ACURASYS trial, PREEMPT trials, anti-HMGCR myopathy literature, BNF, MHRA drug safety updates DISCLAIMER This app is intended for use by qualified healthcare professionals only as a clinical decision-support and educational reference tool. It does not replace individual clinical assessment, local prescribing protocols or official prescribing information. Always consult the current BNF before prescribing.